MedTrace Logo

Cytosorb Therapy in Cardiac Surgery

NCT04309591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2020-03-16

No results posted yet for this study

Summary

Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.

Conditions

  • Cardiopulmonary Surgery
  • Endocarditis
  • Peri-operative Cytokines Levels

Interventions

DEVICE

CytoSorb haemoadsorption (HA) device

CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • David Santer, Dr. med · Universitätsspital Basel, Herzchirurgie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-18
Primary Completion
2019-12-04
Completion
2019-12-04

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04309591 on ClinicalTrials.gov